SynthyraThe Platform
SystemsBiology
inaSecond.
Synthyra maps the full landscape of protein-protein and protein-ligand interactions, revealing the biological networks behind homeostasis, disease, and foundational biology.
The Problem
We grasp the parts. The connections are what's missing.
The human proteome contains over 20,000 proteins and more than 400 million possible pairwise interactions. Life sciences understands individual proteins well, and even many pairwise relationships, but predicting the full network for any organism accurately and in seconds has been impossible until now. What if you could leverage all of that context across your drug development cycle?
0%
of drugs fail clinical trials
0%
because of unmanageable toxicity
$0M+
average cost of late-stage failure
The Engine
SYNTERACT-4
A chemical language model that turned protein-protein and protein-ligand interactions into a representation learning problem.
Proteome-Scale
Screen against all 20,000+ human proteins in a single query
Real-Time
375 million interactions per second
Validated
AUROC 0.82 with wet-lab confirmed designs
Value
Three pillars. One platform.
Faster Cures
Accelerate target validation and lead optimization by screening with the full human interactome as context.
Discovery & Design Suite
Rapid Defense
Map how pathogen proteins interact with the human proteome. Enable rapid countermeasure development.
Biodefense Suite
Safer Drugs
Predict off-target interactions and toxicity risks across the full proteome before clinical trials begin.
Safety & Toxicity Suite
Solutions
Purpose-built product suites.
Validation
Built on evidence. Verified in the lab.
Independent benchmarks, third-party wet-lab validation, millions of open-source downloads, billions of protein interactions screened.
+10%
MCC vs current state-of-the-art
Matthews Correlation Coefficient, Bernett Gold-standard PPI benchmark
0.70-0.78 AUROC
Intra-species interactions, consistent across taxonomic diversity
Human, mouse, yeast, D. melanogaster, E. coli, C. elegans, D. rerio, A. thaliana.
0.60-0.90 AUROC
Inter-species interactions, first better than random chance on human|sars-cov-2 interactions
human|sars-cov-2, human|sars-cov, human|hpv, human|hiv, human|hhv, human|mouse, human|rat, human|yeast, BIOGRID
0
AUROC: Core PPI prediction
Internal held-out evaluation sets, homology-aware clustering (30%), C3 dataset split by cluster
0
Novel predicted interactions characterized, 80 more on the way
BLI validation, Adaptyv Bio (third-party)
1.4M+
Model downloads
First version was open-source, global researcher adoption
Binding visualization
EGFR Binder Case Study
Wet-Lab ConfirmedSynthyra designed a variant of cetuximab (in orange), a multi-billion dollar cancer therapeutic, with 87% stronger binding affinity (630 pM Kd) to EGFR (in green). 13 designs tested, 11 strong binders, 1 medium binder, 5 sub 3 nM Kd, 6 stronger than cetuximab.
Biolayer Interferometry on recombinant targets, SDS-PAGE QC. Adaptyv Bio
Ready to see the full picture?
Request access to SYNTERACT and map your proteome in seconds, not years.
or reach out at [email protected]